References
- National Comprehensive Cancer Network Guidelines for Kidney cancer 1/2013. Available from: www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
- McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 2000;27(2):115-23
- Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45(1):8-30
- Ministry of Health, Nicosia. Mecc Joint Registration Project. Cyprus Cancer Registry (CyCR); 2010
- Thompson-coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma:a systematic review and economic evaluation. Health Technol Assess 2010;14(2):1-184, iii-iv
- Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74
- Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
- Elías Moreno FJ, Girón FJ, Vázquez-Polo MA. Negrín: optimal healthcare decisions: comparing medical treatments on a cost-effectiveness basis. Eur J Operat Res 2010;204(1):180-7
- Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii65-71
- EMEA EU/3/04/207. Avaiable from www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000064.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d12b
- Orphan designation, European Medicines Agency. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&mid=WC0b01ac05800240ce
- Briggs A, Sculpher M. An introduction to Markov Modelling for economic evaluation. Pharmacoeconomics 1998;13(4):397-409
- Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. Chapman & Hall/CRC, London, UK. 1996
- Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Value Health 2012;15:804-15
- Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework. Technical report 02-03. Department of Epidemiology and Public Health; University of Leicester, UK: 2004
- Talias M. Optimal decision indices for R&D project evaluation in the pharmaceutical industry: pearson index versus Gittins index. Eur J Operat Res 2007;177(2):1105-12
- Moreno E, Girón FJ, Vázquez-Polo MA. Negrín: optimal healthcare decisions: the importance of the covariates in cost-effectiveness analysis. Eur J Operat Res 2012;218(2):512-22
- Spiegelhalter DJ, Thomas A, Best NG, Lunn D. “WinBUGS Version 1.4 Users Manual”. MRC Biostatistics Unit, Cambridge, UK; 2003. Available from: www.mrc-bsu.cam.ac.uk/bugs/
- Baio G. Bayesian methods in health economics. Chapman Hall, CRC, Boca Raton, FL; 2012
- The Comprehensive R Archive Network. Available from: http://CRAN.R-Project.org
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
- Miller D, Homan S. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994;14(1):52-8
- Purmonen T, Martikainen JA, Soini EJ, et al. Economic evaluation of Sunitinib Malate in second line treatment of metastatic renal cell cancer in Finland. Clin Ther 2008;30(2)
- Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res 2002;11:491
- Hall AR. Generalized method of moments. Oxford University Press, NY, USA; 2004
- Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24
- Ministry of Health, Cyprus. Medical Institute and services law (1978-2000)
- Petrou P. Assessment of tendering for pharmaceuticals as a reimbursement tool in Cyprus Public Health Care Inpatient and Outpatient sector. Manuscript submitted for publication
- Petrou P, Talias M. A framework for applying Health Technology Assessment in Cyprus: thoughts, success stories and recommendations. Value Health Regional Issues 2013;2(2):273-8
- Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines in generalized cost effectiveness analysis. Health Econ 2000;9:235-51
- International Monetary Fund. Cyprus: GDP per capita, current prices. Available from: www.imf.org/external/pubs/ft/weo/2013/01/weodata/weorept.aspx?sy=200&ey=2012&scsm=1&ssd=1&sort=country&ds=.&br=1&c=423&s=NGDPRPC%2CNGDPPC%2CNGDPDPC&grp=0&a=&pr.x=101&pr.y=3
- Welton NJ, Sutton AJ, Cooper NJ, et al. Evidence synthesis for decision making in healthcare. 1st edition. Wiley, West Sussex, UK; 2012
- Oostenbrink J, Al MJ, Oppe M, Rutten-van Mölken MP. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008;11(7):1070-80
- Ades AE, Claxton K. Expected value of sample information calculations in medical decision modelling. Med Decis Making 2004;24:207
- Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996;5:513-24
- Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health 2010;13(1):55-60
- Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011;6:42
- Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases - orphan designation status influences price. Appl Health Econ Health Policy 2011;9:1-5
- National Institute for Health and Clinical Excellence: Citizens Council Report Ultra Orphan Drugs. National Institute for Health and Clinical Excellence 2005, p.19-3, 2010
- Desser AS, Gyrd-Hansen D, Olsen JA, et al. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ 2010;341:c4715
- Scherer FM. The pharmaceutical industry. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics, (Chapter 25). North-Holland, Amsterdam, The Netherlands; 2000. p. 1297-338
- Espín J, Rovira J, García L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. EMINET, University of Granada Spain; 2011
- Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs RD 2011;11(2):113-26
- Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
- Wiggins S, Maness R. Price competition in pharmaceuticals: the case of anti-infectives. Econ Enquiry 2004;42(2):247-64
- A new value-based approach to the pricing of branded medicines Prepared by Medicines, Pharmacy & Industry Group, Department of Health published to DH website
- EMEA Draft guideline on similar biological medicinal products. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf